Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation.
Saved in:
| Title: | Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation. |
|---|---|
| Authors: | Ruan DY; Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, China.; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, China., Wu HX; Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, China.; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, China., Xu Y; Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China., Munster PN; Department of Medicine, University of California San Francisco, San Francisco, CA, USA., Deng Y; Department of Medical Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China., Richardson G; Department of Medical Oncology, Cabrini Hospital - Malvern, Malvern, VIC, Australia., Yan D; Department of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, China., Lee MA; Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, Cancer Research Institute, The Catholic University of Korea, Seoul, South Korea., Lee KW; Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea., Pan H; Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China., Hager S; Medical Oncology Hematology, California Cancer Associates for Research and Excellence, Inc. (cCARE), Fresno, CA, USA., Li X; Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China., Wei S; Department of Gastrointestinal Oncology Surgery, Hubei Cancer Hospital, Wuhan, China., Hou X; Department of Medical Oncology, Henan Cancer Hospital, Zhengzhou, China., Underhill C; Border Medical Oncology Research Unit, Albury Wodonga Regional Cancer Centre, Albury, NSW, Australia., Millward M; Linear Clinical Research & University of Western Australia, Perth, WA, Australia., Nordman I; Medical Oncology Department, Calvary Mater Newcastle, Waratah, NSW, Australia., Zhang J; Medical Oncology Department of Gastrointestinal Cancer, Liaoning Cancer Hospital & Institute, Shenyang, China., Shan J; Department of Medical Oncology, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China., Han G; Department of Liver Diseases and Digestive Interventional Radiology, Xi'an International Medical Center Hospital, Xi'an, China., Grewal J; Medical Oncology Hematology, Norton Cancer Institute, Louisville, KY, USA., Gadgeel SM; Division of Hematology and Oncology, Department of Internal Medicine, Henry Ford Cancer Institute/Henry Ford Health System, Detroit, MI, USA., Sanborn RE; Medical Oncology Department, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA., Huh SJ; Division of Hematology-Oncology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, South Korea., Hu X; Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China., Zhang Y; InventisBio Co. Ltd, Shanghai, China., Xiang Z; InventisBio Co. Ltd, Shanghai, China., Luo L; InventisBio Co. Ltd, Shanghai, China., Xie X; InventisBio Co. Ltd, Shanghai, China., Shi Z; InventisBio Co. Ltd, Shanghai, China., Wang Y; InventisBio Co. Ltd, Shanghai, China., Zhang L; InventisBio Co. Ltd, Shanghai, China., Wang F; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, China. wangfeng@sysucc.org.cn.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, China. wangfeng@sysucc.org.cn., Xu RH; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, China. xurh@sysucc.org.cn.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, China. xurh@sysucc.org.cn. |
| Source: | Signal transduction and targeted therapy [Signal Transduct Target Ther] 2025 Jun 17; Vol. 10 (1), pp. 189. Date of Electronic Publication: 2025 Jun 17. |
| Publication Type: | Journal Article; Clinical Trial, Phase II |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101676423 Publication Model: Electronic Cited Medium: Internet ISSN: 2059-3635 (Electronic) Linking ISSN: 20593635 NLM ISO Abbreviation: Signal Transduct Target Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
